CN114728065A - 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白 - Google Patents

针对cd3和bcma的抗体和自其制备的双特异性结合蛋白 Download PDF

Info

Publication number
CN114728065A
CN114728065A CN202080081975.5A CN202080081975A CN114728065A CN 114728065 A CN114728065 A CN 114728065A CN 202080081975 A CN202080081975 A CN 202080081975A CN 114728065 A CN114728065 A CN 114728065A
Authority
CN
China
Prior art keywords
bcma
seq
antibody
cancer
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080081975.5A
Other languages
English (en)
Chinese (zh)
Inventor
吴辰冰
吴丹青
黄莉妮
张阿敏
帅正蓉
张瑞
宫世勇
巫玄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Epimab Biotherapeutics Co Ltd
Original Assignee
Shanghai Epimab Biotherapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Epimab Biotherapeutics Co Ltd filed Critical Shanghai Epimab Biotherapeutics Co Ltd
Publication of CN114728065A publication Critical patent/CN114728065A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202080081975.5A 2019-11-26 2020-11-26 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白 Pending CN114728065A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019120991 2019-11-26
CNPCT/CN2019/120991 2019-11-26
CN2020111796 2020-08-27
CNPCT/CN2020/111796 2020-08-27
PCT/CN2020/131767 WO2021104371A1 (en) 2019-11-26 2020-11-26 Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Publications (1)

Publication Number Publication Date
CN114728065A true CN114728065A (zh) 2022-07-08

Family

ID=76130007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080081975.5A Pending CN114728065A (zh) 2019-11-26 2020-11-26 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白

Country Status (11)

Country Link
US (1) US20230002489A1 (cg-RX-API-DMAC7.html)
EP (2) EP4065164A4 (cg-RX-API-DMAC7.html)
JP (3) JP7773466B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240162588A (cg-RX-API-DMAC7.html)
CN (1) CN114728065A (cg-RX-API-DMAC7.html)
AU (2) AU2020390288A1 (cg-RX-API-DMAC7.html)
CA (1) CA3160163A1 (cg-RX-API-DMAC7.html)
IL (2) IL293138A (cg-RX-API-DMAC7.html)
MX (2) MX2022006230A (cg-RX-API-DMAC7.html)
TW (1) TWI774137B (cg-RX-API-DMAC7.html)
WO (1) WO2021104371A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
WO2024131731A1 (zh) * 2022-12-19 2024-06-27 和铂医药(上海)有限责任公司 "κ/λ"Fab-Fab串联多特异性结合蛋白及其制备和应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
IL300760A (en) * 2020-08-24 2023-04-01 Epimab Biotherapeutics Hk Ltd Anti-ROR1 antibodies and related bispecific binding proteins
US20250051443A1 (en) * 2021-10-07 2025-02-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
WO2024012513A1 (en) * 2022-07-13 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025131077A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3多特异性抗体及用途
WO2025168059A1 (zh) * 2024-02-08 2025-08-14 天劢源和生物医药(上海)有限公司 靶向bcma、cd19和cd3的多特异性抗原结合蛋白及其应用
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109803682A (zh) * 2016-08-16 2019-05-24 岸迈生物科技有限公司 单价不对称串联Fab双特异性抗体
CN110156893A (zh) * 2013-12-17 2019-08-23 基因泰克公司 抗cd3抗体及使用方法
WO2019210848A1 (en) * 2018-05-03 2019-11-07 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
EP3310811B1 (en) * 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
JP7014724B2 (ja) * 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Fab免疫グロブリンおよびその使用
IL299221A (en) * 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
CN109535257B (zh) * 2017-09-22 2021-05-28 同润生物医药(上海)有限公司 新型双特异性cd3/cd19多肽复合物
EP3732199A1 (en) * 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156893A (zh) * 2013-12-17 2019-08-23 基因泰克公司 抗cd3抗体及使用方法
CN109803682A (zh) * 2016-08-16 2019-05-24 岸迈生物科技有限公司 单价不对称串联Fab双特异性抗体
WO2019210848A1 (en) * 2018-05-03 2019-11-07 Shanghai Epimab Biotherapeutics Co., Ltd. High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
WO2024131731A1 (zh) * 2022-12-19 2024-06-27 和铂医药(上海)有限责任公司 "κ/λ"Fab-Fab串联多特异性结合蛋白及其制备和应用

Also Published As

Publication number Publication date
IL293138A (en) 2022-07-01
JP7847630B2 (ja) 2026-04-17
MX2024013229A (es) 2024-12-06
AU2024278367A1 (en) 2025-01-09
TW202132347A (zh) 2021-09-01
EP4065164A1 (en) 2022-10-05
EP4483895A2 (en) 2025-01-01
CA3160163A1 (en) 2021-06-03
US20230002489A1 (en) 2023-01-05
JP2026108862A (ja) 2026-06-30
AU2020390288A1 (en) 2022-05-26
JP2025011311A (ja) 2025-01-23
MX2022006230A (es) 2022-06-22
EP4483895A3 (en) 2025-05-28
KR20240162588A (ko) 2024-11-15
JP2023504016A (ja) 2023-02-01
TWI774137B (zh) 2022-08-11
WO2021104371A1 (en) 2021-06-03
KR20220104783A (ko) 2022-07-26
IL316618A (en) 2024-12-01
EP4065164A4 (en) 2024-03-27
JP7773466B2 (ja) 2025-11-19

Similar Documents

Publication Publication Date Title
JP7773466B2 (ja) Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
CN110407941B (zh) Cd39的高亲和力抗体及其用途
JP2023538945A (ja) 抗ror1抗体及び関連の二重特異性結合タンパク質
KR20200061320A (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
KR20160127825A (ko) 항-mcam 항체 및 관련된 사용 방법
EP4101867A1 (en) Anti-cd3 and anti-cd123 bispecific antibody and use thereof
JP7843824B2 (ja) 抗体および使用方法
TW202041537A (zh) 針對lag-3之工程化抗體及自其製備之雙特異性pd-1/lag-3結合蛋白
US12428479B2 (en) CLDN18.2-targeting antibody, bispecific antibody and use thereof
WO2022258015A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
JP7430137B2 (ja) 抗体および使用方法
TW202600594A (zh) 結合構築體(一)
WO2024109657A1 (zh) 抗ccr8抗体及其用途
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
WO2022228545A1 (en) Antibodies and variants thereof against human 4-1bb
EP4428159A1 (en) Melanoma targeting human antibodies and therapeutic uses thereof
BR122025002178A2 (pt) Anticorpos para cd3 e bcma, e proteínas de ligação biespecíficas feitas a partir dos mesmos
HK40016809B (en) High affinity antibodies to cd39 and uses thereof
HK40016809A (en) High affinity antibodies to cd39 and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40067877

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination